Frauke Mcksch

List of Publications by Citations

52 papers	6,314 citations	27 h-index	62 g-index
62 ext. papers	10,074 ext. citations	28.4 avg, IF	6.19 L-index

#	Paper	IF	Citations
52	Convergent antibody responses to SARS-CoV-2 in convalescent individuals. *Nature*, **2020**, 584, 437-442	50.4	1167
51	Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants. *ELife*, **2020**, 9,	8.9	784
50	mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants. *Nature*, **2021**, 592, 616-622	50.4	730
49	Evolution of antibody immunity to SARS-CoV-2. *Nature*, **2021**, 591, 639-644	50.4	652
48	Structures of Human Antibodies Bound to SARS-CoV-2 Spike Reveal Common Epitopes and Recurrent Features of Antibodies. *Cell*, **2020**, 182, 828-842.e16	56.2	485
47	Vaccine Breakthrough Infections with SARS-CoV-2 Variants. *New England Journal of Medicine*, **2021**, 384, 2212-2218	59.2	347
46	Measuring SARS-CoV-2 neutralizing antibody activity using pseudotyped and chimeric viruses. *Journal of Experimental Medicine*, **2020**, 217,	16.6	289
45	Naturally enhanced neutralizing breadth against SARS-CoV-2 one year after infection. *Nature*, **2021**, 595, 426-431	50.4	247
44	Enhanced SARS-CoV-2 neutralization by dimeric IgA. *Science Translational Medicine*, **2021**, 13,	17.5	178
43	Antibody potency, effector function, and combinations in protection and therapy for SARS-CoV-2 infection in vivo. *Journal of Experimental Medicine*, **2021**, 218,	16.6	171
42	Longitudinal Serological Analysis and Neutralizing Antibody Levels in Coronavirus Disease 2019 Convalescent Patients. *Journal of Infectious Diseases*, **2021**, 223, 389-398	7	136
41	Serological Assays Estimate Highly Variable SARS-CoV-2 Neutralizing Antibody Activity in Recovered COVID-19 Patients. *Journal of Clinical Microbiology*, **2020**, 58,	9.7	110
40	Mapping mutations to the SARS-CoV-2 RBD that escape binding by different classes of antibodies. *Nature Communications*, **2021**, 12, 4196	17.4	106
39	Plasma Neutralization of the SARS-CoV-2 Omicron Variant.. *New England Journal of Medicine*, **2021**,	59.2	93
38	Affinity maturation of SARS-CoV-2 neutralizing antibodies confers potency, breadth, and resilience to viral escape mutations. *Immunity*, **2021**, 54, 1853-1868.e7	32.3	83
37	Anti-SARS-CoV-2 receptor-binding domain antibody evolution after mRNA vaccination. *Nature*, **2021**,	50.4	69
36	mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants **2021**,		54

35	Nanobodies from camelid mice and llamas neutralize SARS-CoV-2 variants. *Nature*, **2021**, 595, 278-282	50.4	49
34	Evolution of Antibody Immunity to SARS-CoV-2 **2021**,		43
33	Longitudinal analysis of clinical serology assay performance and neutralising antibody levels in COVID19 convalescents **2020**,		37
32	Bispecific IgG neutralizes SARS-CoV-2 variants and prevents escape in mice. *Nature*, **2021**, 593, 424-428	50.4	36
31	Measuring SARS-CoV-2 neutralizing antibody activity using pseudotyped and chimeric viruses **2020**,		35
30	Plasma neutralization properties of the SARS-CoV-2 Omicron variant. **2021**,		31
29	Author response: Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants **2020**,		31
28	B cell genomics behind cross-neutralization of SARS-CoV-2 variants and SARS-CoV. *Cell*, **2021**, 184, 3205-3221.e24	50.4	34
27	Structures of human antibodies bound to SARS-CoV-2 spike reveal common epitopes and recurrent features of antibodies **2020**,		30
26	Broad cross-reactivity across sarbecoviruses exhibited by a subset of COVID-19 donor-derived neutralizing antibodies. *Cell Reports*, **2021**, 36, 109760	10.6	29
25	Synchronized HIV assembly by tunable PIP changes reveals PIP requirement for stable Gag anchoring. *ELife*, **2017**, 6,	8.9	27
24	Mutational escape from the polyclonal antibody response to SARS-CoV-2 infection is largely shaped by a single class of antibodies **2021**,		27
23	Quantification of phosphoinositides reveals strong enrichment of PIP in HIV-1 compared to producer cell membranes. *Scientific Reports*, **2019**, 9, 17661	4.9	25
22	Development of potency, breadth and resilience to viral escape mutations in SARS-CoV-2 neutralizing antibodies **2021**,		24
21	Antibody potency, effector function and combinations in protection from SARS-CoV-2 infection **2020**,		21
20	Naturally enhanced neutralizing breadth to SARS-CoV-2 after one year **2021**,		19
19	Enhanced SARS-CoV-2 Neutralization by Secretory IgA in vitro **2020**,		15
18	Increased Memory B Cell Potency and Breadth After a SARS-CoV-2 mRNA Boost.. *Nature*, **2022**,	50.4	14

17	Broad cross-reactivity across sarbecoviruses exhibited by a subset of COVID-19 donor-derived neutralizing antibodies **2021**,		13
16	Maturation of the matrix and viral membrane of HIV-1. *Science*, **2021**, 373, 700-704	33.3	10
15	Analysis of memory B cells identifies conserved neutralizing epitopes on the N-terminal domain of variant SARS-Cov-2 spike proteins.. *Immunity*, **2022**,	32.3	10
14	Coagulation factors directly cleave SARS-CoV-2 spike and enhance viral entry **2021**,		9
13	Multimeric nanobodies from camelid engineered mice and llamas potently neutralize SARS-CoV-2 variants **2021**,		8
12	Anti- SARS-CoV-2 Receptor Binding Domain Antibody Evolution after mRNA Vaccination		7
11	Early treatment with a combination of two potent neutralizing antibodies improves clinical outcomes and reduces virus replication and lung inflammation in SARS-CoV-2 infected macaques. *PLoS Pathogens*, **2021**, 17, e1009688	7.6	7
10	Neutralizing activity to SARS-CoV-2 of convalescent and control plasma used in a randomized controlled trial. *Transfusion*, **2021**, 61, 1363-1369	2.9	5
9	HIV-1 matrix-tRNA complex structure reveals basis for host control of Gag localization. *Cell Host and Microbe*, **2021**, 29, 1421-1436.e7	23.4	5
8	Coagulation factors directly cleave SARS-CoV-2 spike and enhance viral entry.. *ELife*, **2022**, 11,	8.9	4
7	Increased Potency and Breadth of SARS-CoV-2 Neutralizing Antibodies After a Third mRNA Vaccine Dose. **2022**,		3
6	Longitudinal variation in SARS-CoV-2 antibody levels and emergence of viral variants: implications for the ability of serological assays to predict immunity **2021**,		2
5	Bispecific antibody neutralizes circulating SARS-CoV-2 variants, prevents escape and protects mice from disease **2021**,		2
4	Conserved Neutralizing Epitopes on the N-Terminal Domain of Variant SARS-CoV-2 Spike Proteins. **2022**,		1
3	A recombinant protein SARS-CoV-2 candidate vaccine elicits high-titer neutralizing antibodies in macaques **2020**,		1
2	A Recombinant Protein SARS-CoV-2 Candidate Vaccine Elicits High-titer Neutralizing Antibodies in Macaques **2021**,		1
1	Comparison of SARS-CoV-2 serological assays for use in epidemiological surveillance in Scotland.. *Journal of Clinical Virology Plus*, **2021**, 1, 100028		